Clinical Advances in Gastrointestinal Cancers
FDA Grants Full Approval to Pembrolizumab for Patients with MSI-High dMMR Tumors
April 13, 2023
The FDA converted its accelerated approval for pembrolizumab for adult and pediatric patients with advanced microsatellite instability-high (MSI-high) or mismatch-repair deficient (dMMR) solid tumors to full approval...
Regorafenib-Based Triplet Demonstrated Promising Activity for Patients with MSS Colorectal Cancer
April 13, 2023A phase 1 clinical study of regorafenib in combination with ipilimumab and nivolumab in patients with advanced microsatellite stable colorectal cancer established a recommended phase 2 dose of 80 mg per day for the agent...
Robotic Surgery Superior to Laparoscopic Surgery for Middle, Low Rectal Cancer
December 9, 2022Short-term outcomes from a multi-center study have demonstrated that robotic surgery is superior to conventional laparoscopic surgery for middle and low rectal cancer...
Roche Withdraws Tecentriq From U.S. Bladder Cancer Indication
December 1, 2022Roche has voluntarily withdrawn the U.S. indication of Tecentriq for treating a form of bladder cancer following consultation with the Food and Drug Administration (FDA)...
Merck's Combination Cancer Therapy Succeeds In Late-Stage Study
November 23, 2022On Tuesday, therapy involving cancer drug Keytruda in combination with chemotherapy met the main goal of a late-stage study for treating a type of gastric cancer...
Cancer Diagnoses Lag After Screenings Fall During Pandemic, U.S. Study Finds
November 21, 2022Screenings for a variety of common cancers have not returned to pre-pandemic levels, potentially leading to diagnoses later in the course of the disease when it may be more difficult to treat successfully...
